In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Nestlé Gets Serious With Seres Deal

Executive Summary

The January Nestlé Health-Seres alliance nets Seres one of the biggest up-front payments in several years for an ex-US product license, while Nestlé shows its continuing commitment to building a portfolio of GI nutritional therapeutics – an area where development efforts have been slow to take shape.

You may also be interested in...



Seres Banks Serious Cash To Drive Microbiome Therapy To Market

Seres and rival Ferring are both hoping to have the first-ever FDA-approved microbiome therapeutic but the US firm has secured a strong commercial partner in Nestlé's Aimmune pharma arm to drive SER-109 over the finishing line.

Microbiotica: Wellcome Spin-Out Exploits Unique Microbe Collection

Emerging Company Profile: Microbiotica, a UK biotech spin-out from the Wellcome Trust Sanger Institute announced late last year, says it has unique capabilities in culturing and sequencing the human bacterial microbiome that will be of use to develop bacterial mixes for therapeutic use.

Start-Up Quarterly Statistics, Q1 2016

Start-ups raised $1.8 billion in Q1 2016. Biopharma companies penned 33 alliances; 14 acquisitions were signed (11 in the biopharma industry).

Related Content

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

IV004487

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel